Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry - PubMed
5 hours ago
- #opportunistic infection
- #hematological malignancy
- #human metapneumovirus
- Human metapneumovirus (hMPV) is an underrecognized respiratory pathogen in immunocompromised patients, particularly those with hematological malignancies.
- A multinational registry analysis compared hMPV outcomes with influenza and SARS-CoV-2 in hematological malignancy patients, revealing comparable severity and mortality rates.
- Key findings include a 64% hospitalization rate, 19% ICU admission rate, and 8% 30-day mortality among hMPV patients, with most receiving only supportive care.
- Chronic renal disease significantly increased mortality risk (HR 20.9).
- Despite similar outcomes to influenza and SARS-CoV-2, hMPV patients received fewer targeted interventions due to lack of specific treatments or vaccines.
- The study highlights the need for enhanced clinical awareness, diagnostics, and investment in prevention and therapeutics for hMPV in high-risk populations.